skip navigation
A B C D E F G H I J K L M N O P Q

Test Identifier Information

 
Registration CodeCTGN
Method

Fluorescence in situ hybridisation (FISH) on formalin fixed paraffin embedded tissue (FFPE) slides using a probe specific to the HER2 (ERBB2) locus and a chromosome 17 control probe.

Diagnostic Use / Indications

The HER2 (ERBB2) protein is expressed at a low level in normal cells, but over-expressed in 18-20% of breast cancers.

Patients with HER2 gene amplification are eligible for treatment with trastuzumab (Herceptin®), which targets HER2 and has proved remarkably effective in patients with a tumour over-expressing the protein, in both metastatic and adjuvant settings.

External Price$372.61(Exclusive of GST)
  

Specimen Collection

 
Pre-Testing Requirements

 Please call ahead if there is particular urgency for a result.

 

Specimen Collection Protocols
  • Only tissue preserved in neutral buffered formalin and paraffin embedded is suitable for use. NB: Samples de-calcified in Formic acid are not suitable for FISH as this process affects the integrity of the DNA.

  • Tissue specimens should be cut into sections of 2-4µm, ideally on poly-L-lysine slides.

  • Ensure one H&E slide and 2-3 unprocessed slides are supplied.

  • Slide must be clearly labelled with two patient identifiers, matching those on the request form.

  • The H&E slide must be assessed by a pathologist prior to receipt, and appropriate areas for FISH analysis should be clearly marked.
Patient SpecimenParaffin Embedded Tumour Tissue Slides
Sample Delivery to LabIn slide-holders or boxes at ambient temperature
  

CHLabs Laboratory

 
DepartmentHaematology - Cytogenetics
Contact Details Email Email
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Contact Phone Number03 3786 007 ext 86007
Test AvailabilitySamples are processed 3 times per week
Turnaround Time1-10 days
Interpretation

Current cases are analysed and reported in accordance with CAP/ASCO recommendations (2013):

Wolff et al: Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013 Nov 31(31): 3997-4014.

For cases received prior to 1st November 2013, the CAP/ASCO Guidelines (2007) were followed:

Wolff A C, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007 Jan 1;25(1): 118-45.

Please contact this laboratory if you have any questions regarding these changes.

Delphic Number Test Number9033

CHL Follow us on Facebook